bioRxiv Science⌕ Search

Biology subjects

Batista, V. L.

Publications and source records attributed to Batista, V. L..

3 recordsLinked to original sources

CORONAVIRUS INFECTION ACCELERATES EXPERIMENTAL OSTEOPOROSIS THROUGH THE ACTIVATION OF OSTEOCLASTS

Coronavirus infection is increasingly associated with systemic inflammation and extrapulmonary sequelae, including bone loss. However, the impact of coronavirus infection on hosts with pre-existing osteoporosis remains poorly understood. Here, we investigated the effects of infection with the murine coronavirus MHV-A59 on bone remodeling in a mouse model of ovariectomy-induced osteoporosis. Female C57BL/6 mice underwent ovariectomy (OVX) or sham surgery and, after establishment of the osteoporotic phenotype (14 days post-surgery), were intranasally infected with MHV-A59. Clinical, inflammatory, and femur parameters were evaluated throughout acute and chronic phases of infection using histopathological, micro-computed tomography and biochemical analyses. In vitro infection assays with bone-marrow derived macrophages (BMDM) and BMDM-differentiated osteoclasts from Sham and OVX mice were also performed. MHV-A59 induced comparable lung inflammation in Sham and OVX mice. In contrast, infection accelerated bone resorption in OVX mice during the acute phase (5 dpi), whereas in non-osteoporotic animals, infection induced significant bone loss at later stages (60 dpi). These alterations were associated with increased osteoclast differentiation and activity and with elevated levels of osteometabolic and inflammatory mediators, including RANKL, CCL2, CCL3, CCL5, and TGF-{beta}1. In vitro, MHV-A59 infection enhanced the expression of osteoclast-associated markers, including Rank, Traf6, Nfac1, and cathepsin K, and inflammatory mediators by BMDM and osteoclasts. Importantly, these responses were significantly more pronounced in cells derived from OVX mice. Collectively, our findings demonstrate that coronavirus infection promotes bone resorption and accelerates early bone loss in the context of estrogen deficiency, highlighting enhanced osteoclast activity as a potential mechanism underlying this infection-induced phenotype.

cell biology↗

P2Y12-P-Selectin Mediated Platelet Activation Drives Dengue-Associated Thrombocytopenia

Dengue virus (DENV) infection frequently causes thrombocytopenia, a hallmark of severe disease. The underlying mechanisms of this condition remain incompletely understood. Using a murine model that mirrors human hematologic and inflammatory responses, we show that DENV impairs megakaryopoiesis, causing necrotic loss of bone marrow megakaryocytes and compensatory thrombopoietin elevation. Megakaryocyte-derived platelets exhibit mitochondrial dysfunction and phosphatidylserine exposure, consistent with apoptosis. Systemically, DENV drives P-selectin- dependent platelet activation and platelet-monocyte aggregates, accompanied by increased plasmatic chemokines (CXCL4, CCL5, CXCL1) and vascular leakage in target organs such as liver and lungs, reflecting heightened thromboinflammation. Pharmacologic blockade of P-selectin or inhibition of P2Y12 with clopidogrel restored platelet counts, rescued megakaryocyte numbers, and reduced systemic inflammation. Collectively, these findings demonstrate for the first time in an in vivo model that DENV-induced thrombocytopenia arises from combined megakaryocyte impairment and platelet hyperactivation and highlight platelet-targeted interventions as potential therapeutic strategies. KEY POINTSO_LIDENV disrupts platelet production and survival via megakaryocyte necrosis and intramedullary platelet apoptosis, driving thrombocytopenia. C_LIO_LIDENV triggers thrombocytopenia via P-selectin platelet activation; blocking it with antibody P-selectin or clopidogrel reduces inflammation. C_LI

immunology↗

Cyclodextrin-Based Delivery of the Annexin A1 Mimetic Peptide Ac2-26 Enhances Anti-Inflammatory Effects and PreventsDengue-Induced Lethality in Combination with AntiviralTherapy

Severe dengue is characterized by systemic inflammation, cytokine storm, vascular leakage, and hemorrhagic manifestations, largely driven by the host immune response to dengue virus (DENV) infection. Despite its burden, no licensed antivirals or host-directed therapies are currently available. Our group has previously identified Annexin A1 (AnxA1) as an endogenous regulator of inflammation in dengue. Treatment with the AnxA1 peptidomimetic, Ac2-26, improved clinical outcomes in murine models of severe dengue by promoting resolution of inflammation without affecting viral control. To explore new delivery strategies, we developed a novel formulation of Ac2-26 complexed with hydroxypropyl-{beta}-cyclodextrin (CDX-Ac2-26). In DENV-2-infected A129 mice, both intraperitoneal and oral CDX-Ac2-26 improved clinical scores and reversed thrombocytopenia. Notably, CDX-Ac2-26 reduced mast cell degranulation, MCPT-1 plasma levels, and CCL2 expression in spleen, with no effect on viral titers, indicating a host-targeted mechanism and overcoming the anti-inflammatory effects of the free peptide. Intraperitoneal administration achieved the same efficacy as oral dosing with only one-third of the dose. Importantly, the combination of CDX-Ac2-26 with the antiviral nucleotide analog sofosbuvir fully prevented disease and mortality in infected mice, highlighting a combinatorial effect between host-directed and antiviral therapies. These findings underscore the therapeutic potential of anti-inflammatory/pro-resolving strategies in severe dengue and support the development of CDX-Ac2-26 as a novel adjunctive treatment. Combining anti-inflammatory and antiviral approaches may enhance efficacy and reduce treatment-associated toxicity, offering a promising path for clinical translation. What is already known on this topic?O_LIPlasma levels of Annexin A1 are inversely correlated with the severity of clinical outcomes in dengue virus infection. C_LIO_LIThe Annexin A1 peptidomimetic Ac2-26 exhibits anti-inflammatory and pro-resolving effects against severe dengue in a murine model. C_LI What does this study add?O_LIThe Ac2-26-cyclodextrin complex enhances the anti-inflammatory effects of the peptide against dengue virus infection, allowing for lower dosing and oral administration. C_LIO_LIThe administration of the CDX-Ac2-26 with a nucleoside analog antiviral exhibits a combinatorial effectt, providing complete protection against the lethal outcome of severe dengue. C_LI What is the clinical significance?O_LICurrent dengue treatment relies on symptomatic management, as no directed anti-inflammatory agents or antivirals are currently available. We have identified a novel host-targeted strategy to resolve the disease. C_LIO_LIOur findings strongly support CDX-Ac2-26 as a promising adjunctive treatment strategy in combination with antiviral therapy for severe dengue, highlighting the potential of combinatorial approaches. C_LI

immunology↗